ClinicalTrials.gg
RecruitingNCT07908173Updated Nov 6, 2026

Magnetic Field Maps With NV Application Kit MCG

An observational study in Technical Feasibility and Performance of the Sensor System, Healthy Adult and Healthy Adult Participants, sponsored by Bosch Quantum Sensing GmbH. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Bosch Quantum Sensing GmbH · Observational

Updated Nov 6, 2026Now RecruitingFirst site in Germany+2 moreGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
12
Ages
18 Years and older
Sex
All
01

Study summary

This prospective, single-center, exploratory feasibility study investigates the use of diamond-based nitrogen-vacancy (NV) magnetometers for non-invasive magnetocardiography (MCG). The goal is to assess whether highly sensitive NV sensors can reliably detect and reconstruct the weak magnetic fields generated by the human heart and evaluate their potential for future cardiac diagnostics.

02

Conditions studied

  • Technical Feasibility and Performance of the Sensor System
  • Healthy Adult
  • Healthy Adult Participants
03

In context

Lead sponsor

This is the only study on the registry with Bosch Quantum Sensing GmbH as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of healthy adult volunteers recruited from employees of Robert Bosch GmbH (Corporate Research and Advanced Engineering) and Bosch Quantum Sensing GmbH.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.\|
  • Employee of Robert Bosch GmbH or Bosch Quantum Sensing GmbH.\|
  • Able to provide written .\|
  • Able to comply with study procedures.\|
  • No acute physical or mental impairment.\|
  • No known cardiac disease.\|
  • Legally competent and capable of self-care.\|

Exclusion criteria

Exclusion Criteria:

  • Pregnancy\|
  • Known cardiac, neurological, or psychiatric disease.\|
  • Claustrophobia or agoraphobia.\|
  • Known cardiac arrhythmias.\|
  • Metallic implants, metallic prostheses, or cardiac pacemaker.\|
  • Inability to remain still in the supine position for several minutes.\|
  • Body weight >99 kg.\|
  • Withdrawal of .\|
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
12 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testContactless measurement of cardiac magnetic field.

    Participants will undergo non-invasive cardiac magnetic field measurements using an array of diamond nitrogen-vacancy (NV) magnetometers.

06

What researchers measure

Primary outcomes

  1. Reconstruction of Cardiac Magnetic Field Maps

    * Are the magnetic field signals (on the basis of the single sensor) recorded with the NV Application Kit in accordance with literature in terms of amplitude (in pT) and duration (in ms) of the p-wave, QRS-complex, T-wave? * Are the magnetic field maps recorded with the NV Application Kit in accordance with literature in terms of the number, location, and amplitude of magnetic poles?

    Time frame: up to two weeks

07

Study locations

1 of 1 sites recruiting
  • Robert Bosch GmbH Zentrum für Forschung und Vorausentwicklung
    Renningen, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

2 registry updates since Sep 25, 2026
Status
Not yet recruiting→Recruiting
changed Nov 6, 2026
Sites
1 site added — first site in Germany
Show site
  • Robert Bosch GmbH Zentrum für Forschung und Vorausentwicklung · Renningen, Germany
Nov 6, 2026
Registered
First appeared on the registry
Oct 30, 2026
Show all 2 updates
  1. Nov 6, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Germany
    Show site
    • Robert Bosch GmbH Zentrum für Forschung und Vorausentwicklung · Renningen, Germany
    + 1 other change: verification date
  2. Oct 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07908173
Lead sponsor
Bosch Quantum Sensing GmbH
Collaborators
Robert Bosch GmbH
Responsible party
Eckhard Wehrse (Research Scientist, Robert Bosch GmbH) — Principal investigator
First posted
Oct 30, 2026
Start date
Oct 23, 2026 (estimated)
Primary completion
Feb 28, 2028 (estimated)
Completion
May 30, 2028 (estimated)
Last update
Nov 6, 2026

Study contacts

Eckhard Wehrse, MD
Contact
eckhard.wehrse@de.bosch.com
+4971181129440

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion